DOR BioPharma, Inc. Announces Named Patient Access Program for orBec(R) in Collaboration With Orphan Australia Pty Ltd

Published: Nov 28, 2007

DOR BioPharma, Inc., (OTCBB: DORB) ("DOR" or the "Company") announced today that it has entered into a Letter of Intent with Orphan Australia Pty Ltd. (Orphan Australia), a specialty pharmaceutical company based in Melbourne, Australia, pursuant to which Orphan Australia will act as DOR's Sponsor with regard to the administration of a Named Patient Access Program (NPAP) for orBecĀ® to gastrointestinal Graft-versus-Host disease (GI GVHD) patients in Australia, New Zealand and South Africa.

Back to news